New Phase 3 Data Show Anti-TNF Alpha SIMPONI ARIA® (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis Treatment with SIMPONI ARIA® Showed Significant Inhibition in the Progression of Structural Damage Madrid, Spain, June 14, 2017 ― Janssen Research & Development, LLC (Janssen) announced today results from the pivotal Phase 3 GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA (golimumab) in the treatment of active psoriatic arthritis. In GO-VIBRANT, 75.1 percent of patients with active psoriatic arthritis receiving SIMPONI ARIA 2 mg/kg...
↧